Compugen (NASDAQ:CGEN) Announces Quarterly Earnings Results

Compugen (NASDAQ:CGEN) posted its earnings results on Tuesday. The biotechnology company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.20), Zacks reports. Compugen had a return on equity of 2.61% and a net margin of 2.67%. The firm had revenue of $17.13 million for the quarter, compared to analysts’ expectations of $17.67 million. During the same quarter last year, the company posted ($0.11) EPS.

Compugen Stock Performance

Shares of Compugen stock traded down $0.03 during midday trading on Thursday, hitting $1.56. The company had a trading volume of 85,021 shares, compared to its average volume of 405,169. Compugen has a 52-week low of $0.58 and a 52-week high of $3.03. The stock has a market capitalization of $139.24 million, a P/E ratio of 79.50 and a beta of 2.64. The company has a 50 day moving average of $1.77 and a 200 day moving average of $1.88.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Compugen from a “hold” rating to a “buy” rating in a research report on Thursday, August 15th.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.